What Does It Mean to Have a Lipid-Rich Adrenal Adenoma?
A lipid-rich adrenal adenoma is a benign, non-cancerous tumor of the adrenal gland that contains significant intracellular fat, making it reliably identifiable on imaging and essentially ruling out malignancy—these lesions require hormonal screening but typically need no further imaging follow-up.
Understanding the Diagnosis
A lipid-rich adrenal adenoma is characterized by:
- Low CT attenuation ≤10 Hounsfield units (HU) on non-contrast CT, which reflects high intracellular lipid content 1
- Signal loss on opposed-phase MRI compared to in-phase imaging, confirming intracellular fat 1
- Benign nature with 98% specificity when meeting these imaging criteria 1
The lipid content directly correlates with benignity—there is a strong inverse relationship between the percentage of lipid-rich cells and CT attenuation numbers, with more lipid meaning lower attenuation and higher certainty of benignity 2.
Clinical Significance: What You Need to Do
Immediate Actions Required
You must screen for hormonal excess even though the mass is benign-appearing 1. This includes:
- 1 mg dexamethasone suppression test for mild autonomous cortisol secretion (most common functional abnormality, affecting 20-50% of patients) 3
- Plasma metanephrines/normetanephrines for pheochromocytoma—though research shows this may be unnecessary for lesions <10 HU 4
- Aldosterone-to-renin ratio if hypertension or hypokalemia present
Follow-Up Imaging: Size Matters
For lipid-rich adenomas <4 cm: No further imaging is needed 1, 5, 3. Recent 2025 guidelines are clear that homogeneous lesions ≤10 HU require no ongoing imaging surveillance regardless of size, based on their extremely low malignancy risk.
For lipid-rich adenomas ≥4 cm: Despite benign imaging features, repeat imaging in 6-12 months is recommended due to higher baseline malignancy risk in larger lesions (34% vs 7% for lesions >4 cm vs <4 cm) 1, 5. This is a conservative approach since 91% of adrenocortical carcinomas were >4 cm in large series 1.
What About Hormonal Function?
Lipid-rich adenomas are more commonly found in:
- Primary aldosteronism (significantly more lipid-rich cells than Cushing's syndrome) 2
- Non-functioning tumors (also more lipid-rich than Cushing's adenomas) 2
Interestingly, hormone-secreting lipid-rich adenomas show higher FDG uptake on PET/CT (SUVratio >0.8) compared to non-functioning ones 6. If your patient has an FDG-avid lipid-rich adenoma, intensify hormonal workup as this suggests functional status.
Key Pitfalls to Avoid
Don't skip hormonal screening just because imaging looks benign—up to 30% of adenomas are functioning, with mild autonomous cortisol secretion being most common and associated with cardiovascular morbidity 1, 3
Don't confuse lipid-rich (intracellular fat) with macroscopic fat—myelolipomas contain macroscopic fat visible on CT and also require no follow-up, but they're a different entity 5
Don't order adrenal washout CT for lipid-rich adenomas—if it's already ≤10 HU on non-contrast imaging, you've made the diagnosis; washout studies add cost without benefit and recent guidelines favor MRI over contrast CT for indeterminate lesions 1
In patients <40 years old or pregnant patients, even benign-appearing lesions warrant more aggressive evaluation with MRI (to avoid radiation) and consideration of single follow-up at 12 months due to higher malignancy risk in younger populations 1
The Bottom Line on Prognosis
A 5-year prospective study of lipid-rich adenomas <40 mm with <10 HU showed 4:
- Mean tumor growth of only 1±2 mm over 5 years
- No clinically relevant tumor growth
- No new development of hormonal hypersecretion
- 97% maintained low attenuation on repeat imaging
This means your patient has an excellent prognosis with minimal risk of growth or malignant transformation. The primary concern is detecting subclinical hormonal excess, which carries cardiovascular and metabolic risks if left untreated (15.5% cardiovascular event rate over 50-60 months in patients with mild autonomous cortisol secretion) 3.